These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38521426)

  • 1. Astragaloside IV ameliorates cisplatin-induced liver injury by modulating ferroptosis-dependent pathways.
    Guo J; Le Y; Yuan A; Liu J; Chen H; Qiu J; Wang C; Dou X; Yuan X; Lu D
    J Ethnopharmacol; 2024 Jun; 328():118080. PubMed ID: 38521426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteomic and lipidomic analysis of the mechanism underlying astragaloside IV in mitigating ferroptosis through hypoxia-inducible factor 1α/heme oxygenase 1 pathway in renal tubular epithelial cells in diabetic kidney disease.
    Liu J; Ren J; Zhou L; Tan K; Du D; Xu L; Cao W; Zhang Y
    J Ethnopharmacol; 2024 Nov; 334():118517. PubMed ID: 38972525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Astragaloside IV inhibits adriamycin-induced cardiac ferroptosis by enhancing Nrf2 signaling.
    Luo LF; Guan P; Qin LY; Wang JX; Wang N; Ji ES
    Mol Cell Biochem; 2021 Jul; 476(7):2603-2611. PubMed ID: 33656642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. P-glycoprotein Inhibitor Tariquidar Potentiates Efficacy of Astragaloside IV in Experimental Autoimmune Encephalomyelitis Mice.
    Zhang W; Liu M; Yang L; Huang F; Lan Y; Li H; Wu H; Zhang B; Shi H; Wu X
    Molecules; 2019 Feb; 24(3):. PubMed ID: 30717494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new strategy for Astragaloside IV in the treatment of diabetic kidney disease: Analyzing the regulation of ferroptosis and mitochondrial function of renal tubular epithelial cells.
    Liu J; Yang K; Zhou L; Deng J; Rong G; Shi L; Zhang X; Ren J; Zhang Y; Cao W
    Int Immunopharmacol; 2024 Nov; 141():112794. PubMed ID: 39137626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Astragaloside IV protects blood-brain barrier integrity from LPS-induced disruption via activating Nrf2 antioxidant signaling pathway in mice.
    Li H; Wang P; Huang F; Jin J; Wu H; Zhang B; Wang Z; Shi H; Wu X
    Toxicol Appl Pharmacol; 2018 Feb; 340():58-66. PubMed ID: 29294303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of astragaloside IV against rat myocardial cell apoptosis induced by oxidative stress via mitochondrial ATP-sensitive potassium channels.
    Guan FY; Yang SJ; Liu J; Yang SR
    Mol Med Rep; 2015 Jul; 12(1):371-6. PubMed ID: 25739067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of astragaloside IV on indoxyl sulfate-induced kidney injury in mice via attenuation of oxidative stress.
    Ji C; Luo Y; Zou C; Huang L; Tian R; Lu Z
    BMC Pharmacol Toxicol; 2018 Sep; 19(1):53. PubMed ID: 30176914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Astragaloside IV ameliorates peripheral immunosuppression induced by cerebral ischemia through inhibiting HPA axis.
    Zou Y; Li S; Chen T; Li Z; Gao X; Wang Z
    Int Immunopharmacol; 2022 Apr; 105():108569. PubMed ID: 35091336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Astragaloside IV attenuates myocardial ischemia/reperfusion injury in rats via inhibition of calcium-sensing receptor-mediated apoptotic signaling pathways.
    Yin B; Hou XW; Lu ML
    Acta Pharmacol Sin; 2019 May; 40(5):599-607. PubMed ID: 30030530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Astragaloside IV protects against cisplatin-induced liver and kidney injury via autophagy-mediated inhibition of NLRP3 in rats.
    Qu X; Gao H; Tao L; Zhang Y; Zhai J; Sun J; Song Y; Zhang S
    J Toxicol Sci; 2019; 44(3):167-175. PubMed ID: 30842369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Astragaloside IV alleviates liver injury in type 2 diabetes due to promotion of AMPK/mTOR‑mediated autophagy.
    Zhu Y; Su Y; Zhang J; Zhang Y; Li Y; Han Y; Dong X; Li W; Li W
    Mol Med Rep; 2021 Jun; 23(6):. PubMed ID: 33846768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Compatibility of Tanshinone IIA and Astragaloside IV in attenuating hypoxia-induced cardiomyocytes injury.
    Wang D; Liu Y; Zhong G; Wang Y; Zhang T; Zhao Z; Yan X; Liu Q
    J Ethnopharmacol; 2017 May; 204():67-76. PubMed ID: 28389356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective effects of astragaloside IV on porcine-serum-induced hepatic fibrosis in rats and in vitro effects on hepatic stellate cells.
    Liu H; Wei W; Sun WY; Li X
    J Ethnopharmacol; 2009 Apr; 122(3):502-8. PubMed ID: 19429320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Astragaloside IV prevents high glucose‑induced cell apoptosis and inflammatory reactions through inhibition of the JNK pathway in human umbilical vein endothelial cells.
    You L; Fang Z; Shen G; Wang Q; He Y; Ye S; Wang L; Hu M; Lin Y; Liu M; Jiang A
    Mol Med Rep; 2019 Mar; 19(3):1603-1612. PubMed ID: 30628687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Astragaloside IV regulates the ferroptosis signaling pathway via the Nrf2/SLC7A11/GPX4 axis to inhibit PM2.5-mediated lung injury in mice.
    Wang X; Wang Y; Huang D; Shi S; Pei C; Wu Y; Shen Z; Wang F; Wang Z
    Int Immunopharmacol; 2022 Nov; 112():109186. PubMed ID: 36115280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Astragaloside IV derived from Astragalus membranaceus: A research review on the pharmacological effects.
    Zhang J; Wu C; Gao L; Du G; Qin X
    Adv Pharmacol; 2020; 87():89-112. PubMed ID: 32089240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Astragaloside IV suppresses post-ischemic natural killer cell infiltration and activation in the brain: involvement of histone deacetylase inhibition.
    Dou B; Li S; Wei L; Wang L; Zhu S; Wang Z; Ke Z; Chen K; Wang Z
    Front Med; 2021 Feb; 15(1):79-90. PubMed ID: 33369712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Astragaloside IV from Astragalus membranaceus ameliorates renal interstitial fibrosis by inhibiting inflammation via TLR4/NF-кB in vivo and in vitro.
    Zhou X; Sun X; Gong X; Yang Y; Chen C; Shan G; Yao Q
    Int Immunopharmacol; 2017 Jan; 42():18-24. PubMed ID: 27855303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Astragaloside IV ameliorates motor deficits and dopaminergic neuron degeneration via inhibiting neuroinflammation and oxidative stress in a Parkinson's disease mouse model.
    Yang C; Mo Y; Xu E; Wen H; Wei R; Li S; Zheng J; Li W; Le B; Chen Y; Pan H; Huang S; Wang S; Wang Q
    Int Immunopharmacol; 2019 Oct; 75():105651. PubMed ID: 31401385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.